Summary by Moomoo AI
As of the six months ended June 30, 2024, fosun pharma announced its interim performance, achieving revenue of RMB 20,383 million, a decrease of 4.38% compared to the same period last year. The gross profit was RMB 9,920 million, with a slight decrease in gross margin. During the period, the company realized a profit attributable to the shareholders of the parent company of RMB 1,225 million, a decrease of 31.33% compared to the same period last year. EBITDA was RMB 4,154 million, a decrease of 13.31% compared to the same period last year. The company's operating cash flow was RMB 1,907 million, an increase of 5.36% year-on-year. During the reporting period, the company continued to promote lean management, optimize its asset structure, completed disposals and signed disposals awaiting recovery totaling over RMB 2,000 million. In addition, the company's R&D investment amounted to a total of RMB 2,737 million, with R&D expenses of RMB 1,862 million. The company announced after the reporting period the implementation of a merger and privatization plan for henlius.
